Last reviewed · How we verify

NCT06764550: GR-Barbaro

Molecular and Microbiota Signatures Underlying Colonic Diverticular Disease

Active, enrolled Last updated 8 January 2025
What this trial tests

trial testing This is an observational study, participants are not assigned an intervention as part of the study. in Diverticular Disease of Colon in 150 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
5 March 2020
Primary endpoint
31 July 2024
31 March 2025

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment150
Start date5 March 2020
Primary completion31 July 2024
Estimated completion31 March 2025
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

Adults 18 to 75, any sex, with Diverticular Disease of Colon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The pathogenesis of diverticular disease is likely multifactorial in origin. This project aims to study the involvement of environmental factors in the pathophysiology of diverticular disease, the underlying molecular mechanisms, and alterations in the microbiota.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06764550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing